[go: up one dir, main page]

MX2018002193A - Metodo de uso de quinoxalinilo-piperazinamida. - Google Patents

Metodo de uso de quinoxalinilo-piperazinamida.

Info

Publication number
MX2018002193A
MX2018002193A MX2018002193A MX2018002193A MX2018002193A MX 2018002193 A MX2018002193 A MX 2018002193A MX 2018002193 A MX2018002193 A MX 2018002193A MX 2018002193 A MX2018002193 A MX 2018002193A MX 2018002193 A MX2018002193 A MX 2018002193A
Authority
MX
Mexico
Prior art keywords
methods
piperazinamide
quinoxalinyl
kits
compound
Prior art date
Application number
MX2018002193A
Other languages
English (en)
Inventor
Bok Lee Young
Joong Kim Deog
Mazhari Reza
Edward EMRICH Daniel
Original Assignee
Rexahn Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Pharmaceuticals Inc filed Critical Rexahn Pharmaceuticals Inc
Publication of MX2018002193A publication Critical patent/MX2018002193A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La materia descrita provee métodos que usan y kits que comprenden un compuesto de la fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable del mismo.
MX2018002193A 2015-09-04 2016-09-02 Metodo de uso de quinoxalinilo-piperazinamida. MX2018002193A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562214678P 2015-09-04 2015-09-04
US201662289820P 2016-02-01 2016-02-01
PCT/US2016/050172 WO2017040980A2 (en) 2015-09-04 2016-09-02 Quinoxalinyl-piperazinamide methods of use

Publications (1)

Publication Number Publication Date
MX2018002193A true MX2018002193A (es) 2018-08-01

Family

ID=56896854

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002193A MX2018002193A (es) 2015-09-04 2016-09-02 Metodo de uso de quinoxalinilo-piperazinamida.

Country Status (9)

Country Link
US (3) US9969698B2 (es)
EP (1) EP3344250A2 (es)
JP (1) JP2018526392A (es)
KR (1) KR20180049015A (es)
CN (1) CN108025009A (es)
AU (1) AU2016316056A1 (es)
CA (1) CA2994184A1 (es)
MX (1) MX2018002193A (es)
WO (1) WO2017040980A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
EP0188040B1 (en) 1985-01-11 1991-08-14 Abbott Laboratories Limited Slow release solid preparation
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
KR100501022B1 (ko) 1998-07-28 2005-07-18 다나베 세이야꾸 가부시키가이샤 장내 적소 방출형 제제
CA2587891C (en) 2004-11-17 2010-08-31 Rexhan Pharmaceuticals, Inc. 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)alylpiperazine derivatives
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
US9744167B2 (en) * 2013-06-28 2017-08-29 Rexahn Pharmaceuticals, Inc. Nanoparticulate compositions and formulations of piperazine compounds

Also Published As

Publication number Publication date
CN108025009A (zh) 2018-05-11
US20200231553A1 (en) 2020-07-23
US9969698B2 (en) 2018-05-15
WO2017040980A2 (en) 2017-03-09
US10570101B2 (en) 2020-02-25
WO2017040980A3 (en) 2017-05-11
EP3344250A2 (en) 2018-07-11
CA2994184A1 (en) 2017-03-09
US20170066726A1 (en) 2017-03-09
AU2016316056A1 (en) 2018-02-01
KR20180049015A (ko) 2018-05-10
JP2018526392A (ja) 2018-09-13
US20180290985A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
MX2021003311A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MA39749A (fr) Dérivés de pipéridine-dione
TW201613872A (en) IRAK4 inhibiting agents
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12017501523A1 (en) Selective bace1 inhibitors
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
JOP20190163B1 (ar) منشط nrf2
AU2016330503A8 (en) Therapeutic compounds and methods of use thereof
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
MX2019010640A (es) Formas cristalinas de acido obeticolico.
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
MX2019005504A (es) Potenciadores de bmp.
UA100342U (ru) Применение натриевой соли гидрогенсульфида как средства для снижения гастротоксичности нестероидных противовоспалительных средств